Enanta Pharmaceuticals Inc ENTA
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2013-03-21 |
| Shares Out. | 29,080,000 |
| Website | enanta.com/ ↗ |
| Phone | 13026365400 |
| Employees | 120 |
| Revenue | $17.2M |
| Gross Profit | $17.2M |
| Net Income | -$13.1M |
| Free Cash Flow | -$9.6M |
| Total Assets | $314.7M |
| Total Liabilities | $198.1M |
| Equity | $116.6M |
About Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Enanta Pharmaceuticals Inc is a publicly traded company under the ticker symbol ENTA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-07-01)